Dual variable domain immunoglobulins and uses thereof

Patent metadata

Field	Value
Publication number	US-9029508-B2
Application number	US-43146009-A
Country	US
Kind code	B2
Filing date	Apr 28, 2009
Priority date	Apr 29, 2008
Publication date	May 12, 2015
Grant date	May 12, 2015

Abstract

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

First claim

We claim:

1. A binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein
VD1 is a first variable domain;
VD2 is a second variable domain;
C is a constant domain;
X1 is a linker;
X2 is an Fc region;
n is 0 or 1;

wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, and wherein the binding protein is capable of binding VEGF and DLL4, wherein the first and second polypeptide chains of the binding protein comprise:
SEQ ID NOs: 239 and 240,
SEQ ID NOs: 411 and 412,
SEQ ID NOs: 413 and 414,
SEQ ID NOs: 419 and 420,
SEQ ID NOs: 435 and 436,
SEQ ID NOs: 445 and 446,
SEQ ID NOs: 449 and 450,
SEQ ID NOs: 453 and 454,
SEQ ID NOs: 461 and 462,
SEQ ID NOs: 465 and 466,
SEQ ID NOs: 469 and 470,
SEQ ID NOs: 473 and 474,
SEQ ID NOs: 475 and 476,
SEQ ID NOs: 477 and 478,
SEQ ID NOs: 479 and 480,
SEQ ID NOs: 481 and 482,
SEQ ID NOs: 483 and 484,
SEQ ID NOs: 485 and 486,
SEQ ID NOs: 489 and 490,
SEQ ID NOs: 493 and 494,
SEQ ID NOs: 497 and 498,
SEQ ID NOs: 501 and 502,
SEQ ID NOs: 503 and 504,
SEQ ID NOs: 507 and 508,
SEQ ID NOs: 509 and 510,
SEQ ID NOs: 511 and 512,
SEQ ID NOs: 513 and 514,
SEQ ID NOs: 517 and 518,
SEQ ID NOs: 525 and 526,
SEQ ID NOs: 529 and 530,
SEQ ID NOs: 533 and 534,
SEQ ID NOs: 537 and 538,
SEQ ID NOs: 541 and 542,
SEQ ID NOs: 543 and 544,
SEQ ID NOs: 545 and 546,
SEQ ID NOs: 557 and 558,
SEQ ID NOs: 559 and 560,
SEQ ID NOs: 561 and 562,
SEQ ID NOs: 585 and 586,
SEQ ID NOs: 589 and 590, or
SEQ ID NOs: 593 and 594.

2. The binding protein according to claim 1 , wherein the first polypeptide chain is a heavy chain and n is 0 or 1 for (X2)n, and wherein the second polypeptide chain is a light chain and n is 0 for (X2)n.

3. The binding protein according to claim 1 , wherein the first and second polypeptide chains of the binding protein comprise:
SEQ ID NOs: 239 and 240,
SEQ ID NOs: 445 and 446,
SEQ ID NOs: 449 and 450,
SEQ ID NOs: 453 and 454,
SEQ ID NOs: 465 and 466,
SEQ ID NOs: 473 and 474,
SEQ ID NOs: 477 and 478,
SEQ ID NOs: 481 and 482,
SEQ ID NOs: 485 and 486,
SEQ ID NOs: 489 and 490,
SEQ ID NOs: 493 and 494,
SEQ ID NOs: 497 and 498,
SEQ ID NOs: 503 and 504,
SEQ ID NOs: 507 and 508,
SEQ ID NOs: 509 and 510,
SEQ ID NOs: 511 and 512,
SEQ ID NOs: 513 and 514,
SEQ ID NOs: 517 and 518,
SEQ ID NOs: 525 and 526,
SEQ ID NOs: 529 and 530,
SEQ ID NOs: 533 and 534,
SEQ ID NOs: 537 and 538,
SEQ ID NOs: 541 and 542,
SEQ ID NOs: 543 and 544,
SEQ ID NOs: 545 and 546,
SEQ ID NOs: 557 and 558,
SEQ ID NOs: 559 and 560,
SEQ ID NOs: 561 and 562,
SEQ ID NOs: 585 and 586,
SEQ ID NOs: 589 and 590, or
SEQ ID NOs: 593 and 594.

4. The binding protein according to claim 1 , comprising two first polypeptide chains and two second polypeptide chains and four functional target binding sites.

5. The binding protein according to claim 1 , wherein the Fc region is a variant sequence Fc region.

6. The binding protein according to claim 1 , wherein the Fc region is an Fc region from an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.

7. The binding protein according to claim 1 , wherein the binding protein is a crystallized binding protein.

8. A binding protein conjugate comprising a binding protein according to claim 1 , the binding protein conjugate further comprising an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent.

9. The binding protein conjugate according to claim 8 , wherein the imaging agent is a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin.

10. The binding protein conjugate according to claim 9 , wherein the radiolabel is 3 H, 14 C, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I, 177 Lu, 166 Ho, or 153 Sm.

11. The binding protein conjugate according to claim 8 , wherein the therapeutic or cytotoxic agent is an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, a toxin, or an apoptotic agent.

12. An isolated nucleic acid encoding the binding protein amino acid sequence according to claim 1 .

13. A vector comprising the isolated nucleic acid according to claim 12 .

14. A host cell comprising the vector according to claim 13 .

15. The host cell according to claim 14 , wherein the host cell is a prokaryotic cell, Escherichia coli , a eukaryotic cell, an animal cell, a plant cell, a fungal cell, a yeast cell, an Sf9 cell, a mammalian cell, an avian cell, an insect cell, a CHO cell or a COS cell.

16. A method of producing a binding protein, comprising culturing the host cell of claim 14 in culture medium under conditions sufficient to produce the binding protein.

17. A pharmaceutical composition comprising the binding protein according to claim 1 and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition according to claim 17 , further comprising at least one additional therapeutic agent.

19. A method of determining the presence, amount, or concentration of VEGF and/or DLL4 in a test sample by an immunoassay comprising contacting the test sample with at least one binding protein of claim 1 and at least one detectable label.

20. A kit for assaying a test sample for the presence, amount, or concentration of VEGF and/or DLL4, said kit comprising (a) instructions for assaying the test sample for VEGF and/or DLL4 and (b) at least one binding protein comprising the binding protein of claim 1 .

21. The binding protein of claim 1 , wherein the first and second polypeptide chains of the binding protein comprise:
SEQ ID NOs: 489 and 490,
SEQ ID NOs: 517 and 518,
SEQ ID NOs: 503 and 504,
SEQ ID NOs: 507 and 508,
SEQ ID NOs: 525 and 526,
SEQ ID NOs: 511 and 512,
SEQ ID NOs: 529 and 530, or
SEQ ID NOs: 543 and 544.

22. The binding protein of claim 1 , wherein the first and second polypeptide chains of the binding protein comprise:
SEQ ID NOs: 411 and 412,
SEQ ID NOs: 413 and 414,
SEQ ID NOs: 475 and 476,
SEQ ID NOs: 477 and 478,
SEQ ID NOs: 479 and 480,
SEQ ID NOs: 481 and 482,
SEQ ID NOs: 483 and 484,
SEQ ID NOs: 485 and 486,
SEQ ID NOs: 511 and 512,
SEQ ID NOs: 513 and 514,
SEQ ID NOs: 543 and 544,
SEQ ID NOs: 545 and 546,
SEQ ID NOs: 559 and 560, or
SEQ ID NOs: 561 and 562.

Assignees

• Ghayur Tariq
• Morgan-Lappe Susan E
• Reilly Edward B
• Kingsbury Gillian A
• Phillips Andrew
• Wang Jieyi
• Bell Randy L
• Norvell Suzanne M
• Li Yingchun
• Liu Junjian
• Ying Hua
• Abbvie Inc

Inventors

• Ghayur Tariq
• Morgan-Lappe Susan E
• Reilly Edward B
• Kingsbury Gillian A
• Phillips Andrew
• Wang Jieyi
• Bell Randy L
• Norvell Suzanne M
• Li Yingchun
• Liu Junjian
• Ying Hua

Classifications

• A61P9/06

  Antiarrhythmics · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P39/00

  General protective or antinoxious agents · CPC title

• A61P9/12

  Antihypertensives · CPC title